Cue Biopharma. has been granted a patent for T-cell modulatory multimeric polypeptides (TMMPs) designed to modulate T cell activity. These TMMPs incorporate type 1 diabetes-associated peptide epitopes and are intended for therapeutic applications in treating individuals with type 1 diabetes. GlobalData’s report on Cue Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cue Biopharma, CAR-T cell based therapies was a key innovation area identified from patents. Cue Biopharma's grant share as of July 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
T-cell modulatory polypeptides for treating type 1 diabetes
The granted patent US12029782B2 introduces a novel T-cell modulatory multimeric polypeptide (TMMP) designed to enhance T-cell responses. The TMMP is characterized as a homodimer formed from two heterodimers. Each heterodimer consists of two distinct polypeptides: a first polypeptide with a specific amino acid sequence (SEQ ID NO: 185) and a second polypeptide with another defined sequence (SEQ ID NO: 186). Notably, the heterodimers are covalently linked through disulfide bonds that are formed between the immunoglobulin Fc polypeptides present in the second polypeptide of each heterodimer, establishing a stable multimeric structure.
Additionally, the patent claims a pharmaceutical composition that incorporates the TMMP described in the first claim. This composition is expected to leverage the unique structural properties of the TMMP to modulate T-cell activity, potentially offering therapeutic applications in immunology and related fields. The specificity of the amino acid sequences and the structural configuration of the TMMP may provide a foundation for further research and development in T-cell modulation therapies.
To know more about GlobalData’s detailed insights on Cue Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
